Effect in vitro of apolipoprotein A-V on the structure and functions of recombinant high density lipoprotein

Biochemical and Biophysical Research Communications

Volumn 401, Issue 3, 2010, Pages 473-479

  Zhang, Xinbo ^a   Wang, Jian ^a   Chen, Baosheng ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Antioxidation; Apolipoprotein A I; Apolipoprotein A V; High density lipoprotein; Structure

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A5; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN;

ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BINDING AFFINITY; CONTROLLED STUDY; ELECTRON MICROSCOPY; HUMAN; HUMAN CELL; LIPID STORAGE; MACROPHAGE; PARTICLE SIZE; PRIORITY JOURNAL; TURBIDITY;

APOLIPOPROTEINS A; ATHEROSCLEROSIS; CELL LINE; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MACROPHAGES; OXIDATION-REDUCTION; PROTEIN CONFORMATION; PROTEIN TRANSPORT; RECOMBINANT PROTEINS;

EID: 77958154186     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.09.084     Document Type: Article

References (29)

1. Drexel H., Amann F.W., Beran J., Rentsch K., Candinas R., Muntwyler J., Luethy A., Gasser T., Follath F. Plasma triglycerides and three lipoprotein cholesterol fractions are independent predictors of the extent of coronary atherosclerosis. Circulation 1994, 90:2230-2235.
2. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am. J. Cardiol. 2000, 86:943-949.
3. Pennacchio L.A., Olivier M., Hubacek J.A., Cohen J.C., Cox D.R., Fruchart J.C., Krauss R.M., Rubin E.M. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 2001, 294:169-173.
4. O'Brien P.J., Alborn W.E., Sloan J.H., Ulmer M., Boodhoo A., Knierman M.D., Schultze A.E., Konrad R.J. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin. Chem. 2005, 51:351-359.
5. Baroukh N., Bauge E., Akiyama J., Chang J., Afzal V., Fruchart J.C., Rubin E.M., Fruchart-Najib J., Pennacchio L.A. Analysis of apolipoprotein A5, c3, and plasma triglyceride concentrations in genetically engineered mice, Arterioscler. Thromb. Vasc. Biol. 2004, 24:1297-1302.
6. Singh I.M., Shishehbor M.H., Ansell B.J. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 2007, 298:786-798.
7. Nelbach L., Shu X., Konrad R.J., Ryan R.O., Forte T.M. Effect of apolipoprotein A-V on plasma triglyceride, lipoprotein size, and composition in genetically engineered mice. J. Lipid Res. 2008, 49:572-580.
8. Qu S., Perdomo G., Su D., D'Souza F.M., Shachter N.S., Dong H.H. Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic mice. J. Lipid Res. 2007, 48:1476-1487.
9. Grosskopf I., Baroukh N., Lee S.J., Kamari Y., Harats D., Rubin E.M., Pennacchio L.A., Cooper A.D. Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants. Arterioscler. Thromb. Vasc. Biol. 2005, 25:2573-2579.
10. Schaap F.G., Rensen P.C., Voshol P.J., Vrins C., van der Vliet H.N., Chamuleau R.A., Havekes L.M., Groen A.K., van Dijk K.W. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J. Biol. Chem. 2004, 279:27941-27947.
11. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease The Framingham Study. Am. J. Med. 1977, 62:707-714.
12. Shah P.K., Nilsson J., Kaul S., Fishbein M.C., Ageland H., Hamsten A., Johansson J., Karpe F., Cercek B. Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation 1998, 97:780-785.
13. Kaul S., Rukshin V., Santos R., Azarbal B., Bisgaier C.L., Johansson J., Tsang V.T., Chyu K.Y., Cercek B., Mirocha J., Shah P.K. Intramural delivery of recombinant apolipoprotein A-IMilano/phospholipid complex (ETC-216) inhibits in-stent stenosis in porcine coronary arteries. Circulation 2003, 107:2551-2554.
14. Nissen S.E., Tsunoda T., Tuzcu E.M., Schoenhagen P., Cooper C.J., Yasin M., Eaton G.M., Lauer M.A., Sheldon W.S., Grines C.L., Halpern S., Crowe T., Blankenship J.C., Kerensky R. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003, 290:2292-2300.
15. Pajkrt D., Doran J.E., Koster F., Lerch P.G., Arnet B., van der Poll T., Ten Cate J.W., van Deventer S.J. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J. Exp. Med. 1996, 184:1601-1608.
16. Mansouri R.M., Bauge E., Gervois P., Fruchart-Najib J., Fievet C., Staels B., Fruchart J.C. Atheroprotective effect of human apolipoprotein A5 in a mouse model of mixed dyslipidemia. Circ. Res. 2008, 103:450-453.
17. Naumann A., Heeren J., Bruns O.T., Thiery J., Teupser D., Merkel M. Apoprotein A5 (APOA5) reduces atherosclerosis in mice. Atheroscler. Suppl. 2008, 9:37-38.
18. Zhu X., Wu G., Zeng W., Xue H., Chen B. Cysteine mutants of human apolipoprotein A-I: a study of secondary structural and functional properties. J. Lipid Res. 2005, 46:1303-1311.
19. Wang Y., Zhu X., Wu G., Shen L., Chen B. Effect of lipid-bound apoA-I cysteine mutants on lipopolysaccharide-induced endotoxemia in mice. J. Lipid Res. 2008, 49:1640-1645.
20. Sun G., Bi N., Li G., Zhu X., Zeng W., Wu G., Xue H., Chen B. Identification of lipid binding and lipoprotein lipase activation domains of human apoAV. Chem. Phys. Lipids 2006, 143:22-28.
21. Chen C.H., Albers J.J. Characterization of proteoliposomes containing apoprotein A-I: a new substrate for the measurement of lecithin: cholesterol acyltransferase activity. J. Lipid Res. 1982, 23:680-691.
22. Koizumi J., Kano M., Okabayashi K., Jadhav A., Thompson G.R. Behavior of human apolipoprotein A-I:phospholipid and apoHDL:phospholipid complexes in vitro and after injection into rabbits. J. Lipid Res. 1988, 29:1405-1415.
23. Beckstead J.A., Oda M.N., Martin D.D., Forte T.M., Bielicki J.K., Berger T., Luty R., Kay C.M., Ryan R.O. Structure-function studies of human apolipoprotein A-V: a regulator of plasma lipid homeostasis. Biochemistry 2003, 42:9416-9423.
24. Nilsson S.K., Lookene A., Beckstead J.A., Gliemann J., Ryan R.O., Olivecrona G. Apolipoprotein A-V interaction with members of the low density lipoprotein receptor gene family. Biochemistry 2007, 46:3896-3904.
25. Draper H.H., Hadley M. Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol. 1990, 186:421-431.
26. Cho K.H. Synthesis of reconstituted high density lipoprotein (rHDL) containing apoA-I and apoC-III: the functional role of apoC-III in rHDL. Mol. Cells 2009, 27:291-297.
27. Guo G.L., Santamarina-Fojo S., Akiyama T.E., Amar M.J., Paigen B.J., Brewer B., Gonzalez F.J. Effects of FXR in foam-cell formation and atherosclerosis development. Biochim. Biophys. Acta 2006, 1761:1401-1409.
28. Toshima S., Hasegawa A., Kurabayashi M., Itabe H., Takano T., Sugano J., Shimamura K., Kimura J., Michishita I., Suzuki T., Nagai R. Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 2000, 20:2243-2247.
29. Aviram M., Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic. Biol. Med. 2004, 37:1304-1316.